ArticleWorld journal of urology2025
Efficacy of Bacillus Calmette-Guérin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.BJU international · 2026Article
- Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSequential gemcitabine and docetaxel (Gem/Doce) therapy is increasingly regarded as a promising substitute for Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC). This study compares the efficacy of Gem/Doce and BCG in managing Ta high-grade (TaHG) NMIBC.
methodsPatients with TaHG NMIBC treated with Gem/Doce or BCG therapy following transurethral resection of the bladder tumor (TURBT) were analyzed. A one-year maintenance protocol when applicable. Recurrence-free survival (RFS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis, and multivariate Cox regression identified predictors for recurrence and progression.
resultsA total of 172 patients (99 BCG, 73 Gem/Doce) were included, with longer median follow-up in the BCG group (47 vs. 20 months, p < 0.001). Progression was more frequent in the Gem/Doce group (18% vs. 4%, p = 0.003). BCG demonstrated superior 2-year RFS for any recurrence (62.3% vs. 37.9%, p = 0.018), high-grade recurrence (72.7% vs. 61.3%, p = 0.049), and 2-year PFS (97.4% vs. 83.3%, p < 0.0001). Maintenance therapy improved high-grade RFS (p = 0.019) and PFS (p = 0.033) in the Gem/Doce group but had no significant impact in the BCG group. On multivariate analysis, Gem/Doce was an independent risk factor for any recurrence (HR = 2.03, p < 0.001), high-grade recurrence (HR = 1.95, p = 0.03), and progression (HR = 13.55, p < 0.001).
conclusionBCG appears to provide superior recurrence and progression control over Gem/Doce in TaHG NMIBC with a one-year maintenance protocol. Future studies should explore extended maintenance regimens, particularly for Gem/Doce.
Indexed as
Identifiers
40293462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.